Aspire Biopharma Holdings (ASBP) Change in Accured Expenses (2022 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Change in Accured Expenses of -$316955.0 for Q1 2026, down 185.48% year-over-year from $370802.2 in Q1 2025, and down 127.37% quarter-over-quarter from $1.2 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Change in Accured Expenses (2022 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Change in Accured Expenses for 5 consecutive years, with -$316955.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 185.48% year-over-year to -$316955.0; the TTM figure through Mar 2026 stood at $841159.0 (up 1429.9% YoY), while the FY2025 annual figure was $1.0 million, up 19.18% from the prior year.
- Change in Accured Expenses declined to -$316955.0 in Q1 2026 per ASBP's latest filing, from $1.2 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.2 million in Q4 2025 and bottomed at -$316955.0 in Q1 2026.
- Historically, Change in Accured Expenses has averaged $63629.8 across 5 years, with a median of $12239.0 in 2022.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses tumbled 257.73% — and 2024, when it surged 822.18%.
- Aspire Biopharma Holdings' Change in Accured Expenses stood at $84618.0 in 2022, then plunged by 43.72% to $47626.0 in 2023, then plunged by 546.93% to -$212855.0 in 2024, then jumped by 644.09% to $1.2 million in 2025, then plunged by 127.37% to -$316955.0 in 2026.
- Business Quant data shows ASBP's Change in Accured Expenses at -$316955.0 in Q1 2026, $1.2 million in Q4 2025, and -$111026.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | 272,474.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 272,474.00 |
| Jun 30, 2026 | 272,474.00 |
| Mar 31, 2026 | -316,955.00 |
| Mar 31, 2026 | -316,955.00 |
| Dec 31, 2025 | 1.16 Mn |
| Dec 31, 2025 | 1.16 Mn |
| Mar 31, 2025 | -111,026.00 |
| Mar 31, 2025 | -111,026.00 |
| Jun 30, 2024 | -212,855.00 |
| Jun 30, 2024 | -212,855.00 |
| Mar 31, 2024 | 213,005.00 |
| Mar 31, 2024 | 213,005.00 |
| Dec 31, 2023 | 47,626.00 |
| Dec 31, 2023 | 47,626.00 |
| Sep 30, 2023 | 2,712.00 |
| Sep 30, 2023 | 2,712.00 |
| Jun 30, 2023 | -102,065.00 |
| Jun 30, 2023 | -102,065.00 |
| Mar 31, 2023 | 23,098.00 |
| Mar 31, 2023 | 23,098.00 |